They have shown that galectin-9, through its cytoplasmic AMP-activated protein kinase (AMPK) activity, can influence various health conditions affected by AMPK, including obesity, diabetes, cancer, and immune responses, and may be part of the mechanism of action of some diabetes medicines, including metformin. This evidence concerns the gene LGALS9 and obesity due to melanocortin 4 receptor deficiency.